We are analyzing https://link.springer.com/article/10.1007/s10456-010-9184-y.

Title:
Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy | Angiogenesis
Description:
In ischemic retinopathies, unrelieved hypoxia induces the formation of architecturally abnormal, leaky blood vessels that damage retina and ultimately can cause blindness. Because these newly formed blood vessels are functionally defective, they fail to alleviate underlying hypoxia, resulting in more pathological neovascularization and more damage to retina. With an established model of ischemic retinopathy, we investigated inhibition of glycogen synthase kinase-3β (GSK-3β) as a means for improving the architecture and functionality of pathological blood vessels in retina. In vitro, hypoxia increased GSK-3β activity in retinal endothelial cells, reduced β-catenin, and correspondingly impaired integrity of cell/cell junctions. Conversely, GSK-3β inhibitors restored β-catenin, improved cell/cell junctions, and enhanced the formation of capillary cords in three-dimensional collagen matrix. In vivo, GSK-3β inhibitors, at appropriately moderate doses, strongly reduced abnormal vascular tufts, reduced abnormal vascular leakage, and improved vascular coverage and perfusion during the proliferative phase of ischemia-driven retinal neovascularization. Most importantly, these improvements in neovasculature were accompanied by marked reduction in retinal hypoxia, relative to controls. Thus, GSK-3β inhibitors offer a promising strategy for alleviating retinal hypoxia by correcting key vascular defects typically associated with ischemia-driven neovascularization.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Telecommunications
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, pubmed, google, scholar, cas, retinal, vascular, angiogenesis, endothelial, synthase, smith, glycogen, senger, cell, growth, retinopathy, neovascularization, hypoxia, inhibitors, factor, gskβ, kinase, research, model, ischemic, sci, biol, chem, privacy, cookies, content, reduces, hoang, retina, pathological, cells, med, publish, search, access, gsk, res, mol, kinasebeta, data, information, log, journal, moderate, inhibition,

Topics {✒️}

high-molecular-weight fluorescein-labeled dextrans glycogen synthase kinase-3β glycogen synthase kinase-3beta reduced β-catenin month download article/chapter glycogen synthase kinase-3 gsk-3β inhibitors offer bkca channel-dependent mechanisms growth factor-1 receptor neovascularizing ocular diseases ischemia-driven retinal neovascularization improved cell/cell junctions hypoxia-induced expression appropriately moderate doses article angiogenesis aims gsk-3β inhibitors vascular biology research reduces retinal hypoxia pathological vascular phenotype related subjects improves cardiac function reduces vascular leakage full article pdf endothelial cell migration retinal endothelial cells alleviating retinal hypoxia rho activity critically improved vascular coverage pathological blood vessels cell/cell junctions multi-tasking kinase ischemia-driven neovascularization oxygen-induced retinopathy privacy choices/manage cookies de fougerolles ar unrelieved hypoxia induces alleviate underlying hypoxia gsk-3β anti-apoptotic signaling ocular angiogenesis gsk-3beta increased dietary intake article hoang leaky blood vessels harvard medical school pathological neovascularization investigated inhibition retinal hypoxia retinal angiogenesis european economic area

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy
         description:In ischemic retinopathies, unrelieved hypoxia induces the formation of architecturally abnormal, leaky blood vessels that damage retina and ultimately can cause blindness. Because these newly formed blood vessels are functionally defective, they fail to alleviate underlying hypoxia, resulting in more pathological neovascularization and more damage to retina. With an established model of ischemic retinopathy, we investigated inhibition of glycogen synthase kinase-3β (GSK-3β) as a means for improving the architecture and functionality of pathological blood vessels in retina. In vitro, hypoxia increased GSK-3β activity in retinal endothelial cells, reduced β-catenin, and correspondingly impaired integrity of cell/cell junctions. Conversely, GSK-3β inhibitors restored β-catenin, improved cell/cell junctions, and enhanced the formation of capillary cords in three-dimensional collagen matrix. In vivo, GSK-3β inhibitors, at appropriately moderate doses, strongly reduced abnormal vascular tufts, reduced abnormal vascular leakage, and improved vascular coverage and perfusion during the proliferative phase of ischemia-driven retinal neovascularization. Most importantly, these improvements in neovasculature were accompanied by marked reduction in retinal hypoxia, relative to controls. Thus, GSK-3β inhibitors offer a promising strategy for alleviating retinal hypoxia by correcting key vascular defects typically associated with ischemia-driven neovascularization.
         datePublished:2010-09-01T00:00:00Z
         dateModified:2010-09-01T00:00:00Z
         pageStart:269
         pageEnd:277
         sameAs:https://doi.org/10.1007/s10456-010-9184-y
         keywords:
            Retinopathy
            Neovascularization
            Glycogen synthase kinase-3β
            Hypoxia
            Endothelial cell
            β-catenin
            Cancer Research
            Biomedicine
            general
            Cell Biology
            Cardiology
            Ophthalmology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig7_HTML.gif
         isPartOf:
            name:Angiogenesis
            issn:
               1573-7209
               0969-6970
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mien V. Hoang
               affiliation:
                     name:Beth Israel Deaconess Medical Center and Harvard Medical School
                     address:
                        name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lois E. H. Smith
               affiliation:
                     name:Children’s Hospital Boston and Harvard Medical School
                     address:
                        name:Department of Ophthalmology, Children’s Hospital Boston and Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Donald R. Senger
               affiliation:
                     name:Beth Israel Deaconess Medical Center and Harvard Medical School
                     address:
                        name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy
      description:In ischemic retinopathies, unrelieved hypoxia induces the formation of architecturally abnormal, leaky blood vessels that damage retina and ultimately can cause blindness. Because these newly formed blood vessels are functionally defective, they fail to alleviate underlying hypoxia, resulting in more pathological neovascularization and more damage to retina. With an established model of ischemic retinopathy, we investigated inhibition of glycogen synthase kinase-3β (GSK-3β) as a means for improving the architecture and functionality of pathological blood vessels in retina. In vitro, hypoxia increased GSK-3β activity in retinal endothelial cells, reduced β-catenin, and correspondingly impaired integrity of cell/cell junctions. Conversely, GSK-3β inhibitors restored β-catenin, improved cell/cell junctions, and enhanced the formation of capillary cords in three-dimensional collagen matrix. In vivo, GSK-3β inhibitors, at appropriately moderate doses, strongly reduced abnormal vascular tufts, reduced abnormal vascular leakage, and improved vascular coverage and perfusion during the proliferative phase of ischemia-driven retinal neovascularization. Most importantly, these improvements in neovasculature were accompanied by marked reduction in retinal hypoxia, relative to controls. Thus, GSK-3β inhibitors offer a promising strategy for alleviating retinal hypoxia by correcting key vascular defects typically associated with ischemia-driven neovascularization.
      datePublished:2010-09-01T00:00:00Z
      dateModified:2010-09-01T00:00:00Z
      pageStart:269
      pageEnd:277
      sameAs:https://doi.org/10.1007/s10456-010-9184-y
      keywords:
         Retinopathy
         Neovascularization
         Glycogen synthase kinase-3β
         Hypoxia
         Endothelial cell
         β-catenin
         Cancer Research
         Biomedicine
         general
         Cell Biology
         Cardiology
         Ophthalmology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-010-9184-y/MediaObjects/10456_2010_9184_Fig7_HTML.gif
      isPartOf:
         name:Angiogenesis
         issn:
            1573-7209
            0969-6970
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mien V. Hoang
            affiliation:
                  name:Beth Israel Deaconess Medical Center and Harvard Medical School
                  address:
                     name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lois E. H. Smith
            affiliation:
                  name:Children’s Hospital Boston and Harvard Medical School
                  address:
                     name:Department of Ophthalmology, Children’s Hospital Boston and Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Donald R. Senger
            affiliation:
                  name:Beth Israel Deaconess Medical Center and Harvard Medical School
                  address:
                     name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Angiogenesis
      issn:
         1573-7209
         0969-6970
      volumeNumber:13
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Beth Israel Deaconess Medical Center and Harvard Medical School
      address:
         name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Children’s Hospital Boston and Harvard Medical School
      address:
         name:Department of Ophthalmology, Children’s Hospital Boston and Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Beth Israel Deaconess Medical Center and Harvard Medical School
      address:
         name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mien V. Hoang
      affiliation:
            name:Beth Israel Deaconess Medical Center and Harvard Medical School
            address:
               name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Lois E. H. Smith
      affiliation:
            name:Children’s Hospital Boston and Harvard Medical School
            address:
               name:Department of Ophthalmology, Children’s Hospital Boston and Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Donald R. Senger
      affiliation:
            name:Beth Israel Deaconess Medical Center and Harvard Medical School
            address:
               name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
      name:Department of Ophthalmology, Children’s Hospital Boston and Harvard Medical School, Boston, USA
      name:Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(120)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.7s.

LINK . SPRINGER . COM {}